Utilization of Hospice Services in a Population of Patients With Huntington's Disease

Margaret O Johnson1, Samuel Frank2, Matthew Mendlik1

  • 1Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Insights

Late-stage Huntington's disease (HD) patients in hospice are younger and experience significant symptoms. Despite hospice goals, few HD patients die at home, with most deaths occurring in nursing homes or hospitals.

Area of Science:

  • Neurology
  • Palliative Care
  • Geriatrics

Background:

  • Limited understanding of late-stage Huntington's disease (HD) complications and hospice care.
  • Need to characterize the population of HD patients receiving hospice services.

Purpose of the Study:

  • To describe the characteristics of patients with Huntington's disease (HD) who enrolled in hospice care.

Main Methods:

  • Retrospective cohort study utilizing electronic medical record data.
  • Analysis of 101 Huntington's disease (HD) patients from 12 US hospices (2008-2012).

Main Results:

  • HD patients were younger (median 57 years) than other hospice patients (median 76 years).
  • Common symptoms included pain, anxiety, nausea, and dyspnea, with limited functional status.
  • HD patients had a longer hospice length of stay (42 days) compared to other patients (17 days).
  • Most deaths occurred in nursing homes (40%) or hospitals (37%), with only 23% dying at home.

Conclusions:

  • Huntington's disease (HD) patients in hospice present with a significant symptom burden and functional limitations at a younger age.
  • Despite hospice's focus on home care, a minority of HD patients were able to die at home.
Abstract

Related Concept Videos

Continuing Care01:25

Continuing Care

Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
2.0K
Documentation in Long-Term and Home Healthcare Setting01:29

Documentation in Long-Term and Home Healthcare Setting

Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
1.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
430